SanBio Company Limited (SANBIO COMPANY LIMITED) aksje

SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company's research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction injury, chronic cerebral hemorrhage, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 for peripheral neuropathy; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.